Spyre Therapeutics initiated with a Hold at JonesResearch

JonesResearch initiated coverage of Spyre Therapeutics (SYRE) with a Hold rating and no price target Spyre is a clinical-stage biotech developing half-life extended antibodies for the treatment of inflammatory bowel disease, the analyst tells investors in a research note. The firm sees a balanced risk/reward profile into near-term data catalysts. Spyre ‘s lead monotherapies could drive blockbuster sales, but the opportunities appear priced into the stock, contends JonesResearch.